News By Tag
News By Place
tebu-bio collaborates with Biosensis to distribute their validated research antibodies in Europe
tebu-bio announces today a distributor agreement with research antibody maker Biosensis bringing innovative tools for Life Sciences to European researchers
Under the terms of this agreement, tebu-bio - the European research antibody specialist supplying innovative and guaranteed antibodies and antibody-based kits - will bring European Life Science Researchers easy access to Biosensis’ range of high quality, specialised antibodies for Neuroscience, Stem Cell and Autophagy research, as well as their selection of ELISA kits for the quantification of target antigens in tissue extracts, serum and cell culture. In addition, researcher will also be able to benefit from a growing range of antibodies that have proved valuable in the study of Alzheimer’s & Parkinson’s diseases, Immunology and Obesity.
Biosensis will benefit from the local presence of tebu-bio’s staff all over the Europe and their activities in other innovative fields (proteins, cell biology, ADME-tox, molecular biology and lab services).
“tebu-bio has strived, since 60 years, to bring a selection of reagents, tools & services for Life Sciences researchers. This agreement with Biosensis for Europe, is a unique opportunity for tebu-bio to supply reliable tools to researchers, seeking to use antibodies that have been tested under real experimental conditions, and validated for their applications.”
To learn more about the Biosensis range of products now available through tebu-bio in Europe, please contact Nathalie Bervas (nathalie.bervas@
tebu-bio (Le Perray-en-Yvelines, France) is a well-established organisation recognized by the international scientific community. With local offices (http://www.tebu-
Composed of a team of scientists and business people, Biosensis (Thebarton, Australia) is dedicated to the support of researchers in Academia and industry. The team has many years experience both in basic and applied research as well as in the commercialization of reagent and diagnostic antibodies, and therefore intimately understands the need for researchers to have quality reagents that work.